Clinical trials
MRD clinical trials
Below are recruiting mrd clinical trials, each written for real people, not researchers. We’re tracking 107 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05345860Recruiting
Using MRD results to guide extra treatment after breast surgery
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05286957RecruitingPhase 2
MRD-guided immunotherapy plus chemo after lung cancer surgery
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
Zhengzhou, HenanAges 18–80 - NCT05536505RecruitingPhase 2
After-surgery targeted pill to prevent relapse in EGFR lung cancer
This Phase 2 trial studies whether an EGFR-targeted pill, given after surgery, can reduce the chance of lung cancer coming back. It specifically looks at people whose tumors have certain EGFR changes and where “minimal residual disease” (tiny leftover cancer) is being used to guide treatment.
BeijingAges 18–80 - NCT05940961RecruitingPhase 2
Inotuzumab for MRD-positive B-cell leukemia after transplant
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
Suzhou, JiangsuAges 15–65 - NCT05441566Enrolling by invitation
Checking MRD after surgery in early lung cancer
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
ShenzhenAges 18–100 - NCT05736978RecruitingPhase 2
Tailored treatment for AML based on day-14 MRD test
This phase 2 study tests whether doctors can choose the best AML treatment plan using a special blood/marrow test done on day 14. It may help people who are not good candidates for intensive chemotherapy by adjusting therapy based on early response.
ShanghaiAges 18 years+ - NCT06966440Recruiting
MRD-Guided Chemotherapy After Pancreatic Cancer Surgery
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
ShanghaiAges 18–75 - NCT06477991Recruiting
No surgery after immunotherapy for MSI-H colorectal cancer
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Kunming, YunnanAges 18–75 - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT03509961RecruitingPhase 2
Reducing total body radiation for children with leukemia transplants
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
Birmingham, AlabamaAges 1–25 - NCT04976296Recruiting
Monitoring minimal residual disease after lung cancer surgery
This study checks whether a special blood/tissue test called MRD (minimal residual disease, meaning tiny leftover cancer signals) can help monitor lung cancer after surgery. It may help doctors spot relapse earlier after your tumor has been fully removed.
Guangzhou, GuangdongAges 18 years+ - NCT05203003Recruiting
Testing whether measurable cancer leftovers predict outcomes
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
ParisAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06401421Recruiting
Blood test for tumor DNA after breast cancer chemo
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
Anchorage, AlaskaAges 18 years+ - NCT06886074RecruitingPhase 2
Short blinatumomab to clear leftover B-ALL cells
This trial tests if a shorter course of blinatumomab can remove minimal residual disease (MRD) — tiny traces of leukemia not seen under a microscope — in people with B-cell acute lymphoblastic leukemia after initial treatment.
Monterrey, Nuevo LeónAges 16–60 - NCT06918262Recruiting
MRD-guided local therapy for oligometastatic breast cancer
This study is looking at a test called MRD (minimal residual disease) to see if it can guide decisions about local treatments (like surgery or radiation) for people with breast cancer that has spread to a few spots. It may help doctors know when to use these treatments and when to wait.
Changchun, JilinAges Any age - NCT07120698RecruitingPhase 2
MRD-guided sintilimab after surgery for NSCLC
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
Guangzhou, GuangdongAges 28–75 - NCT07393048Recruiting
Personalized ctDNA test to predict rectal cancer treatment response
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT07441291RecruitingPhase 3
CAR-T vs donor immune cells for residual leukemia after transplant
This study tests whether a therapy using your own immune cells (CAR-T) works better than donor immune cells (DLI) to remove leftover leukemia cells after a stem cell transplant. The goal is to prevent the leukemia from coming back.
Beijing, ChinaAges 3–79 - NCT07371247Enrolling by invitationEarly Phase 1
Adjuvant treatment guided by ctDNA after chemoradiation for esophageal cancer
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
Nanjing, JiangsuAges 18–80 - NCT07504796RecruitingPhase 2
Adding ipilimumab to standard melanoma therapy based on ctDNA
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
New York, New YorkAges 18 years+ - NCT07775950Recruiting
Monitoring and treating colorectal cancer based on tumor DNA
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
Guangzhou, GuangdongAges 18 years+ - NCT05708235RecruitingPhase 2
Blood test monitoring for early breast cancer recurrence
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
A CoruñaAges 18 years+ - NCT07131059Recruiting
Study for MRD-positive AML in remission
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 14 years+
Hear when a new MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mrd?
- Yes. Clin2 currently lists 107 recruiting mrd studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mrd trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mrd trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.